MedTrace Logo

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

NCT00532935 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 517

Last updated 2017-06-09

Study results available
· View outcomes & findings →

Summary

A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes

Conditions

Interventions

DRUG

sitagliptin phosphate (+) metformin hydrochloride

sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period

DRUG

Comparator: pioglitazone

pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-26
Primary Completion
2009-10-23
Completion
2009-10-23

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532935 on ClinicalTrials.gov